We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $159K invested in Array Biopharma Inc in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 316 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 318 → 1 (-317)

100% less funds holding in top 10

Funds holding in top 10: 28 → 0 (-28)

100% less capital invested

Capital invested by funds: $10.5B → $159K (-$10.5B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 316

Holders
1
Holders Change
-317
Holders Change %
-99.69%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-28
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
316
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$943M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$890M
3
BlackRock
BlackRock
New York
-$824M
4
RG
Redmile Group
California
-$405M
5
FCM
Farallon Capital Management
California
-$394M
Name Holding Trade Value Shares
Change 		Change in
Stake
ASN
1
Advisory Services Network
Georgia
$159K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
– -$943M -20,348,961 Closed
Fidelity Investments
3
Fidelity Investments
Massachusetts
– -$890M -19,206,726 Closed
BlackRock
4
BlackRock
New York
– -$824M -17,794,654 Closed
RG
5
Redmile Group
California
– -$405M -8,752,254 Closed
FCM
6
Farallon Capital Management
California
– -$394M -8,500,000 Closed
State Street
7
State Street
Massachusetts
– -$302M -6,509,988 Closed
DKCM
8
Davidson Kempner Capital Management
New York
– -$269M -5,805,612 Closed
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
– -$251M -5,417,747 Closed
Franklin Resources
10
Franklin Resources
California
– -$230M -4,967,892 Closed
Citadel Advisors
11
Citadel Advisors
Florida
– -$201M -4,346,050 Closed
Goldman Sachs
12
Goldman Sachs
New York
– -$187M -4,025,690 Closed
HI
13
HBK Investments
Texas
– -$162M -3,486,602 Closed
PC
14
Paulson & Co
New York
– -$152M -3,275,700 Closed
MF
15
Magnetar Financial
Illinois
– -$148M -3,204,024 Closed
Millennium Management
16
Millennium Management
New York
– -$140M -3,021,920 Closed
AAM
17
Alpine Associates Management
Florida
– -$140M -3,011,700 Closed
Geode Capital Management
18
Geode Capital Management
Massachusetts
– -$139M -3,005,394 Closed
Fidelity International
19
Fidelity International
Bermuda
– -$133M -2,865,000 Closed
BBA
20
Baker Bros. Advisors
New York
– -$132M -2,848,567 Closed
PCM
21
Pentwater Capital Management
Florida
– -$128M -2,765,000 Closed
TAL
22
TIG Advisors LLC
New York
– -$127M -2,737,321 Closed
Northern Trust
23
Northern Trust
Illinois
– -$125M -2,688,021 Closed
CS
24
Credit Suisse
Switzerland
– -$115M -2,479,960 Closed
AA
25
AQR Arbitrage
Connecticut
– -$112M -2,407,065 Closed
1
2 3 4 5

ARRY Hedge Fund Activity: Q3 2019 in Review

1 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2019, worth a combined $159K — down 100% from $10.5B a quarter earlier.

Sellers outnumbered buyers: 316 funds closed out of ARRY and 0 opened new positions — a net loss of 316 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $943M sold.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q3 2019, down from 318 in Q2 2019.
  • Funds reported $159K of Array Biopharma Inc stock for Q3 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Array Biopharma Inc positions in Q3 2019 and 316 closed out, a net change of -316 holders.
  • The largest Array Biopharma Inc seller in Q3 2019 was Vanguard Group, an estimated $943M sold.

Based on aggregated 13F filings for Q3 2019.